ECC 2015 | Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC
Giorgio Scagliotti • 26 Sep 2015
At the European Cancer Congress (ECC) 2015, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomized phase 3 trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage IV non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.
